Faeth’s oral cancer combo clears phase 2, challenging big drug injection therapies
Faeth Therapeutics reported that its oral cancer therapy combination, called Piktor, hit key efficacy goals in a phase 2 trial for endometrial cancer. The drug achieved a 33% confirmed overall response rate, outperforming expectations and offering a pill-based alternative to injectable treatments like ADCs and chemotherapies.
Original image temporarily unavailable
Faeth Therapeutics tested its combination therapy, named Piktor—consisting of serabelisib and sapanisertib—alongside intravenous paclitaxel in 42 patients with advanced or recurrent endometrial cancer. The trial yielded a 33% confirmed overall response rate and a preliminary median progression-free survival of 7.4 months. These results surpass the 30% response rate benchmark set by market analysts, rivaling standard injectable options like immunotherapies and antibody-drug conjugates.
While major pharmaceutical companies heavily focus on injectable antibody-drug conjugates that often rely on topoisomerase I inhibitors, patient resistance remains a challenge. Faeth's oral approach targets the PI3K/AKT/mTOR pathway at multiple points, offering a distinct mechanism of action. The company now plans to discuss a randomized phase 3 trial with the FDA and expects to release data from an ongoing breast cancer study next year.
View selection rationale
Importance 75/100
About this brief
- Content type
- Research summary
- Source type
- Publisher report
- Original source
- Fierce Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.
